Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Research & Development (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Research & Development for 9 consecutive years, with $97.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 1.89% to $97.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $418.8 million, a 5.63% increase, with the full-year FY2025 number at $418.8 million, up 5.63% from a year prior.
  • Research & Development was $97.9 million for Q4 2025 at Denali Therapeutics, down from $101.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $128.8 million in Q1 2023 to a low of $67.9 million in Q4 2021.
  • A 5-year average of $96.7 million and a median of $97.9 million in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 33.25% in 2021, then decreased 16.92% in 2024.
  • Denali Therapeutics' Research & Development stood at $67.9 million in 2021, then grew by 29.33% to $87.8 million in 2022, then rose by 2.22% to $89.7 million in 2023, then increased by 11.2% to $99.8 million in 2024, then fell by 1.89% to $97.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Research & Development are $97.9 million (Q4 2025), $101.9 million (Q3 2025), and $102.7 million (Q2 2025).